Delirium is common in the last weeks or days of life. 1 It can be distressing for patients and those around them. Successful management involves excluding reversible causes of delirium and balancing drugs that may provoke or maintain delirium while appreciating that most patients want to retain clear cognition at the end of life.
Who gets delirium at the end of life?
A systematic review suggested that 13-42% of patients admitted to palliative care inpatient units have delirium. 9 A cohort study of patients with advanced cancer on a palliative care inpatient unit estimated that this rose to 88% in the days and hours before death. 1 Pre-existing cognitive impairment, increased age, an already severe illness state, and infection reduce the brain's ability to resist delirium. 10 Smaller observational studies in cancer patients found that lower performance status, the presence of lung cancer, and shorter time since diagnosis were associated with developing cognitive impairment. 11 A retrospective study in cancer patients reported that male sex and the presence of a primary or metastatic brain tumour predisposed to delirium. 12 Poor prognostic factors for delirium, predictive of non-recovery from the episode, include severe delirium, irreversible precipitating factors, greater degree of cognitive impairment, the hypoactive subtype, and a previous episode of delirium. Delirium caused by hypoxic or metabolic encephalopathy is particularly resistant to reversal, 7 whereas delirium precipitated by drugs, electrolyte abnormalities, and infection are more likely to be reversible. 8 13 
How to identify delirium at the end of life
The core clinical features of delirium are the rapid onset of disturbed attention, fluctuating levels of consciousness, cognitive impairment, psychomotor disturbance, and disruption of the sleep-wake cycle. In our experience, within palliative care these core features often show as purposeless repetitive movements, such as plucking at bed sheets and removing clothes, accompanied by moaning and facial grimacing. Emotional changes, such as fear, anxiety, and agitation are common. Multifocal myoclonus, which may reflect opioid toxicity, renal failure, or other drug related toxicity, may be seen. 14
What you need to know
• Consider delirium in any patient in palliative care who shows a change in behaviour • Investigate underlying causes where appropriate in line with the patient's pre-expressed wishes • Optimise the patient's environment and review drugs • Consider low dose haloperidol first line in people with delirium who are distressed or considered a risk to themselves or others, and in whom conservative management is ineffective or inappropriate
• Additional sedation with lorazepam or midazolam may be appropriate if delirium is irreversible and haloperidol alone does not reduce the distress and risks
Sources and selection criteria
We searched Medline, Clinical Evidence, and the Cochrane Library using the terms delirium, terminal, terminal care, palliative care, palliative medicine, and end of life. Where possible we used systematic reviews and referenced these rather than the individual trials. Our search was limited to citations from 1990 to December 2015. We also searched the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network. Validated tools exist for the screening and diagnosis of delirium (box 3) and can be used by non-specialists as a first step towards diagnosis. It is often not practical to use these tools in severe cases, where cooperation and communication are limited, and they often lack sufficient sensitivity and specificity to be solely relied on. Clinicians often use a global clinical assessment based on detailed history taking, information from care givers, and pattern recognition 7 to make the diagnosis. If the diagnosis is in doubt, colleagues from palliative medicine or psychiatry can provide support.
What investigations are required in palliative care?
Delirium is often a progressive, irreversible process in the last stages of life. However, some causes, particularly drugs, may be reversible and probably account for 30-50% of cases. 1 13 Decisions on whether to investigate should consider the likely nature of the underlying cause, the stage of the illness, and the goals of care pre-established with the patient (box 4). 7
Box 3: Delirium screening and rating tools
Screening tools 
How is delirium managed in palliative care?
There is robust evidence that multicomponent delirium prevention interventions, such as educating nursing staff, assessing and changing drugs, encouraging mobilisation, and improving the patient's environment, can reduce the incidence of delirium by about 30% in high risk medical and surgical inpatients, 21 but evidence to support this approach in palliative care is lacking. 22 Management of delirium in palliative care differs little from other settings in broad terms. The focus is on providing a safe optimised environment (box 5), treating reversible causes, controlling symptoms with drug and non-drug interventions, and communicating with patients and family members.
Treating reversible causes
Review drugs and modify those that cause or potentiate delirium (see box 2).
Overall, only about half of delirium episodes are potentially reversible, although the odds of reversibility are higher when opioids and other psychoactive drugs are precipitants. 1 Because there are often several precipitants or predisposing factors, they all need to be dealt with simultaneously to reverse up to 50% of delirium episodes. 1
If there are concerns about neurotoxicity in patients taking opioids, consider a dose reduction or opioid switch. One observational study of 190 patients treated with opioids showed that 29 of 42 patients who developed confusion and 10 of 15 who developed hallucinations improved on opioid switching. 23 A critical review in 2006 of opioid switching to reduce delirium suggested overall benefit, although the exact benefit was hard to define. 24 A recent review of parenteral nutrition and hydration at the end of life suggested that delirium was the only aspect of terminal symptom control that was likely to benefit from hydration. 25 If an infective cause is suspected, a trial of antibiotics may improve symptoms of delirium.
Symptom control
Medical strategies for delirium focus on reducing agitation and perceptual abnormalities.
Although there are several relevant clinical practice guidelines, 10-28 a Cochrane review in 2012 22 could not make any drug recommendations in end of life care because of the paucity of evidence. End of life care was specifically excluded from the National Institute for Health and Care Excellence (NICE) guidance on delirium, 10 leaving clinicians without pragmatic guidance although, in practice, clinical management is broadly similar.
NICE guidance on delirium recommends considering short term haloperidol or olanzapine in people with delirium who are distressed or considered a risk to themselves or others and in whom verbal and non-verbal de-escalation techniques are ineffective or inappropriate. 10 Although this guidance was not aimed at palliative care, it can help determine when antipsychotics are appropriate in delirium in palliative care.
Haloperidol remains the drug of choice in delirium, despite limited evidence of efficacy from randomised controlled trials (RCTs). 29 Like other antipsychotics, it is associated with extrapyramidal side effects in people over 70 years. 30 It is less sedating than atypical antipsychotics such as risperidone or olanzapine and is useful where less sedation is required, such as in hypoactive states. A small RCT in 30 patients with AIDS related delirium compared haloperidol, chlorpromazine, and lorazepam. 31 Patients in the haloperidol and chlorpromazine • Identify members of staff to be a point of contact to promote a familiar environment and establish continuity
• Encourage family members to visit and help orient the patient groups showed improvement in the delirium rating scale (DRS), whereas those who received lorazepam did not. Those taking lorazepam had greater side effects than those in the chlorpromazine and haloperidol groups. In an uncontrolled observational study of the harms and benefits of haloperidol in palliative care (119 inpatients and outpatients over 10 days), 12% of patients experienced side effects, most commonly somnolence or urinary retention. 32 A recent RCT in 239 delirious palliative care patients (published abstract only) compared placebo, haloperidol, and risperidone over four days. 33 Provisional results suggest patients prescribed haloperidol or risperidone had greater specific delirium symptoms (communication, behaviour, and perceptual disturbance) at study end than those prescribed placebo and also required more midazolam rescue doses.
The low doses of antipsychotics used for delirium are less likely to be associated with extrapyramidal side effects, but avoid combinations of antipsychotics and other dopamine blocking agents such as metoclopramide. Medium to longer term use of antipsychotics is also associated with increased risk of stroke, 34 but these drugs are likely to be used short term in end of life care.
Despite NICE recommending antipsychotic options for delirium, 10 benzodiazepines are preferred when Lewy body dementia or Parkinson's disease coexist because they do not exacerbate extrapyramidal symptoms. Patients with severe agitation (anxious, restless, and aggressive behaviour) may also require a short acting benzodiazepine, such as lorazepam or midazolam. This can be combined with haloperidol.
Management of refractory delirium
A recent systematic review suggested that refractory delirium is the most common reason for palliative sedation at the end of life. 35 Palliative sedation is the monitored use of drugs to reduce awareness in dying patients and relieve suffering from refractory symptoms. The same systematic review found no evidence that the use of such proportionate sedation shortened life, although this finding was based on non-randomised samples.
Palliative sedation may be appropriate for patients with advanced disease at the end of life when the cause of delirium is judged to be irreversible; the manifestations of delirium, such as frightening cognitions and hallucinations, overwhelm the patient; or the patient's behaviour is a threat to him/herself or others. The aim is to control distress during the dying process. Sedation is a consequence rather than the objective of treatment. Sedating antipsychotics such as levomepromazine (methotrimeprazine) are titrated alone or together with a benzodiazepine such as midazolam. These are usually given as a subcutaneous infusion but can be given as regular injections during a titration period or when infusion devices are unavailable. In rare cases where these combinations do not control distress, phenobarbitone injections or infusions can be used, although these recommendations are not based on evidence from clinical trials and would require specialist palliative medicine expertise.
Helping families understand delirium
Delirium can be distressing for families. 36 The hypoactive form is often missed by clinicians, and family members may be better placed to report the subtle changes in presentation that may herald its onset. A detailed observational study of the experience of delirium in inpatients with cancer found that mean scores for distress were higher in the spouses and family care givers who had witnessed the delirium than in affected patients. 37 Furthermore, a qualitative study of 37 family care givers found that many thought that analgesics caused the delirium. 36 The same study found that distress was lowest in care givers who were educated about the risk of delirium before it occurred.
Discuss delirium, the likely causes, and what it means for the patient with family care givers (box 6). Where poor prognostic factors are identified, discuss this with families so they are aware that their relative may be entering the last few days of life and that sedation may be needed for distressing or refractory symptoms.
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Provenance and peer review: Not commissioned; externally peer reviewed. • Explain that this may be the start of a more rapid and irreversible decline in the patient's health
• Whether the delirium is reversible or not, provide reassurance that control of the patient's distress will be your priority
Education into practice
• Do you routinely observe and ask during consultations whether your medically ill patients are alert and orientated?
• Does your team know how to recognise and manage delirium that is distressing to patients or putting them or others at risk of harm?
Questions for future research
• What strategies are effective for the prevention of delirium in palliative care? 38
• How effective or harmful are antipsychotics compared with placebo, and at what doses?
• How effective or otherwise are non-pharmacological strategies?
• What are the most effective strategies for supporting families of those affected by delirium? 
Further sources of information for patients and professionals
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